Biotech buyouts.When looking at Immunomedics 2020 buyout by Gilead for $21b, that price represents a 108% premium to the previous days closing price of the stock. If Onc were to be purchased today for $8b, that represents somewhere close to an 11000% premium over our current stock price. Should we be tempering our expectations? I'm confident, but I just wonder if BP will go for something like this. Excuse me if my numbers are off.